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Natalizumab (NTZ) was the first approved humanized monoclonal antibody in highly active
relapsing remitting MS (RRMS). Because of the mechanism of inhibiting the migration of
immune cells through the blood-brain barrier into the CNS, NTZ is associated with an in-
creased risk of progressive multifocal leukoencephalopathy (PML) by the John Cunningham
virus (JCV). Infections with other neurotropic viruses are rarely reported.1,2 We present a case
of rapid retinal necrosis induced by varicella zoster virus (VZV) in a patient with RRMS under
long-term NTZ treatment.
Case report
A 46-year-old Caucasian man diagnosed with RRMS in 2001 was initially treated with in-
terferon beta-1a. After 2 relapses, therapy was switched to NTZ in 2006. Subsequently, the
patient presented neither clinical nor radiographic disease activity until January 2018. With the
exception of a treatment interruption between 2014 and 2017, he received a total of 127 NTZ
infusions. In January 2018, progressive visual loss over 2 days occurred in his left eye. During
clinical examination, visual acuity was only 0.2. Apart from a residual subtle paresis of the left
leg, no other new neurologic deficits were present. Brain imaging was comparable to a scan
acquired 6 months prior, with no signs of new inflammatory lesions. Unexpectedly, ophthal-
mologic examination showed a retinal vasculitis and focal infiltration in the outer part of the
retina (figure 1, A–C). CSF measurement revealed a pleocytosis of 122 cells/μL, positive CSF
oligoclonal bands, elevated protein levels of 564 mg/L, albumin quotient (CSF/serum) of 9.1,
lactate of 2.0 mmol/L, and isolated VZV intrathecal antibody index of 30.2 (<1.5). PCR
amplification of VZV-DNA was positive in CSF (8,175 copies/mL), whereas other microbi-
ologic CSF and serologic analyses were without pathologic findings. We diagnosed VZV-
associated retinal vasculitis and retinitis and initiated IV treatment with acyclovir (3 × 900mg/d
for 16 days). Two days after starting acyclovir treatment, retinal infiltration progressed to acute
retinal necrosis. Therapy was escalated using intravitreal ganciclovir injections (2 mg twice, at
days 1 and 4 after progression) (figure 1B) and oral prednisolone (50 mg/d) after negative CSF
results for bacterial pathogens. This therapy hindered progression of retinal necrosis, and visual
acuity of the left eye improved to 0.5. Fundoscopy showed regressive retinal necrosis with
beginning repigmentation of VZV lesions (figure 1C). After 14 days, CSF parameters improved
to 47 cells/μL and 97.5 copies/mL of VZV-DNA. Acyclovir was switched to oral application
(800 mg twice daily) for long-term control of retinal vasculitis. Teriflunomide treatment was
started 2 months after the last NTZ infusion to prevent future relapses.
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Discussion
Owing to the NTZ-associated PML incidence due to JCV,
NTZ-treated RRMS patients are closely monitored by se-
rologic and radiologic means. Other neurotropic virus
infections have rarely been identified as critical pathogens in
this context, both in clinical trials and in postmarketing
observations.3 However, several authors have described
VZV-induced meningitis2 and CNS vasculitis4 with associ-
ated retinitis in patients treated with NTZ,5 which highlights
the potential role of other neurotropic virus infections aside
from PML.
In contrast to previous reports about VZV reactivation, our
patient presented neither with clinical signs of meningeal
involvement, nor was he showing any evidence of cerebral
vasculitis apart from retinitis, despite the highly elevated
CSF cell count. Others have reported patients with
vasculitis-mediated ischemic stroke or encephalitis with
surprisingly normal5 or only slightly elevated CSF cell
levels.4 It is tempting to speculate that the short time span
between clinical onset and treatment initiation (3 days)
prevented further cerebral affection. Fortunately, our pa-
tient could be saved from developing amaurosis, possibly
because of an early and aggressive systemic and additional
local antiviral treatment. An early concomitant drug ther-
apy should therefore be considered in future cases, showing
progression to retinal necrosis after initiation of IV antiviral
treatment.
Moreover, without close ophthalmologic examination, the
isolated vision loss could have easily been misdiagnosed as an
optic neuritis, a typical syndrome in patients with RRMS.
High doses of steroids are commonly indicated in this sce-
nario6 with possible detrimental consequences to the patient’s
eye sight.
Of interest, NTZ-treated MS patients have a significant in-
crease in serologic anti–VZV-IgG levels compared with
healthy controls, indicating a tendency toward a subclinical
VZV reactivation before clinical manifestation.7 Conse-
quently, this could imply an increased risk of VZV infections
similar to the elevated risk of PML under long-term NTZ
treatment.
In addition to the diagnosis of MS relapse or PML, physicians
should consider other opportunistic infections when new
neurologic deficits present under long-term NTZ treatment.
Figure Fundoscopic examination of the VZV-infected left eye over time
(A) Healthy right eye and (B.a) affected left eye during initial fundoscopy.Multiple focal infiltrations in the peripheral retina are present in the left eye. (B.b) The
fluorescent angiography (white box of B.a) illustrates the (peri)-vasculitis as exudates around retinal vessels resulting in white sheathing (arrows). The follow-
up examination (C) after 3 days indicates progression of infiltration due to acute retinal necrosis. Regression of retinal necrosis and beginning of repig-
mentation of several infiltrates are observed 24 days after initiation of antiviral treatment (D).
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